ClinicalTrials.gg
CompletedNCT05777174Updated Mar 28, 2025Results posted

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

A Phase 3 interventional study of MB-102 and MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) in Kidney Diseases, Kidney Injury and Kidney Failure, sponsored by MediBeacon. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Primary conditionRenal InsufficiencyRegistry: Kidney DiseasesReclassifiedWhy we changed it
Registry
Kidney Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Renal Insufficiency
Why
  1. The study's listed conditions name Renal Insufficiency, a narrower term within Kidney Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MediBeacon · Phase 3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
69th of 468
149 · median 32
Started
2023
with 20 others
Phase 3
45 of 553
1 open now
Registered
482nd of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 69th largest by enrollment of the 468 interventional ones that give a count, is one of 21 that started in 2023, is one of 45 in phase 3, and was the 482nd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound. Adults with kidney function ranging from estimated glomerular filtration rate (eGFR) \<120 to >15 mL/min/1.73 m2 and spanning the entire range of human skin colors as defined by the Fitzpatrick Skin Scale (FSS) were included in the study.

The main questions that the study aimed to answer were:

  • To establish that the MB-102 transdermal fluorescence assessed GFR using the MediBeacon Transdermal GFR System with the TGFR reusable sensor with disposable adhesive ring was comparable to the measured MB-102 plasma GFR.
  • To evaluate the safety and effectiveness of the MediBeacon Transdermal GFR System and the TGFR reusable sensor with disposable adhesive ring for the non-invasive transdermal fluorescence detection of MB-102 in participants

On dosing day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. When this was completed, participants then received a single dose of MB-102. Blood samples were collected and fluorescent measurements were taken over a 12- or 24-hour (or longer) period, depending upon enrollment group. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body. Following completion of the treatment period, participants returned to the study center approximately 1 week later for a safety follow-up visit. Researchers compared the results to see if the transdermal GFR measurements were comparable to the measured plasma GFR.

03

Conditions studied

  • Kidney Diseases
  • Kidney Injury
  • Kidney Failure

Browse trials for

Keywords

  • Glomerular Filtration Rate
  • Relmapirazin
  • Iohexol
  • Pharmacokinetics
  • Transdermal fluorescence detection
  • MB-102
04

In context

Renal Insufficiency Reclassified

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

This study's enrollment of 149 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

MediBeacon is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Compared within Renal Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible female non-pregnant participants who are either not of or willing to use adequate during the trial
  • Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post-dose
  • For women of childbearing potential, the participant should have a negative serum pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly i.e. abstinence, oral contraceptive either combined or progesterone alone; injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, IUD device or system or male partner sterilization
  • Men will not donate sperm during the study and for 1 month following the last dose of study drug.
  • Participants who are capable of directly providing and who can comply with the requirements and restrictions required by the protocol
  • Adequate venous access sufficient to allow blood sampling per protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Participants positive for COVID-19 at the time of dosing
  • Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior to the initial dose of the study medication; or more than 499 mL within 56 days prior to the initial dose of study medication
  • Non-steroidal anti-inflammatory (NSAID) use within 3 days of MB-102 dosing
  • The participant has participated in a clinical trial and has received an product within the following time ranges: prior to the first dosing day in the current study: either 30 days or 5 half-lives of the investigational product (whichever duration is longer).
  • History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)
  • History of severe allergic reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, MB-102 or other related products (intolerance to a drug is not considered a drug allergy).
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
  • Significant scaring, tattoos or alterations in pigmentation on the sternum or other sensor location testing areas that would alter sensor readings versus other areas of the skin
  • Use of tanning sprays, tanning products etc. on the upper chest within 2 weeks of dosing day
  • Use make-up, lotions, Vaseline or other products on the area of the upper chest on the day prior to or the day of dosing
  • Any serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, or psychiatric condition that in the opinion of the investigator would limit the participant's ability to complete study requirements or may put the participant at increased risk or compromise the interpretability of study results.
  • Currently receiving dialysis
  • Currently anuric
  • Positive serum pregnancy test
  • Participants with an > 120 mL/min/1.73m\^2
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Participants with eGFR ≥ 70 mL/min/1.73 m^2

    A TGFR Reusable Sensor with Disposable Adhesive Ring was placed on participants' chests at least 15 minutes prior to dosing on treatment day, and the MediBeacon Transdermal GFR System was initiated to collect background fluorescence. After the collection of background fluorescence, a single dose of MB-102 (130 mg) was administered intravenously to participants with estimated glomerular filtration rate (eGFR) eGFR ≥ 70 mL/min/1.73 m\^2. Approximately half of the participants had Fitzpatrick Scale Type I, II or III, and half had Type IV, V and VI skin color type. Blood samples and fluorescent measurements were collected over 12 hours.

    Drug: MB-102 · Device: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

  • Experimental
    Participants with eGFR < 70 mL/min/1.73 m^2

    A TGFR Reusable Sensor with Disposable Adhesive Ring was placed on participants' chests at least 15 minutes prior to dosing on treatment day, and the MediBeacon Transdermal GFR System was initiated to collect background fluorescence. After the collection of background fluorescence, a single dose of MB-102 (130 mg) was administered intravenously to participants with estimated glomerular filtration rate eGFR \< 70 mL/min/1.73 m\^2. Approximately half of the participants had Fitzpatrick Scale Type I, II or III, and half had Type IV, V and VI skin color type. Blood samples and fluorescent measurements were collected over 24 hours.

    Drug: MB-102 · Device: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

Interventions

  • DrugMB-102

    18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds

    Also known as: Relmapirazin

  • DeviceMediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)

    On treatment day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System was initiated to collect background fluorescence. When this was completed, participants received a single dose of MB-102. Fluorescent measurements were collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body.

07

What researchers measure

Primary outcomes

  1. Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR)

    The performance measure of P30 is defined as the proportion of transdermal derived GFR values that are within 30% of the measured plasma-derived GFR across all participants. The comparison of transdermal derived glomerular filtration rate (tGFR) with respect to the plasma-derived indexed glomerular filtration rate (nGFR) was calculated with a double-sided 97% confidence interval (CI). The performance goal was 0.85, and success for the study was defined as a lower limit of the 97% CI greater than 0.85.

    Time frame: Up to 24 hours following the study dose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration

    An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

    Time frame: From the time of dosing through the follow-up visit, up to 10 days

  2. Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device

    An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

    Time frame: From the time of dosing through the follow-up visit, up to 10 days

08

Results

Posted Mar 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneParticipants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2
Started8465
Completed8465
Not completed00

Outcome measures

PrimaryCorrelation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR)

The performance measure of P30 is defined as the proportion of transdermal derived GFR values that are within 30% of the measured plasma-derived GFR across all participants. The comparison of transdermal derived glomerular filtration rate (tGFR) with respect to the plasma-derived indexed glomerular filtration rate (nGFR) was calculated with a double-sided 97% confidence interval (CI). The performance goal was 0.85, and success for the study was defined as a lower limit of the 97% CI greater than 0.85.

Time frame:
Up to 24 hours following the study dose
Reported as:
Number · Proportion of tGFR within 30% of nGFR
Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR)
Proportion of tGFR within 30% of nGFRParticipants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2
Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR)0.950 (0.817 to 0.995)0.971 (0.836 to 1.00)
SecondaryNumber of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration

An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

Time frame:
From the time of dosing through the follow-up visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration
ParticipantsParticipants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2
Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration11
SecondaryNumber of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device

An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.

Time frame:
From the time of dosing through the follow-up visit, up to 10 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device
ParticipantsParticipants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2
Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device00

Adverse events

Collected over Treatment-emergent adverse events were collected from the time of dosing through the follow-up visit, up to 10 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With eGFR ≥ 70 mL/Min/1.73 m^20/84 (0%)0/84 (0%)2/84 (2.4%)
Participants With eGFR < 70 mL/Min/1.73 m^20/65 (0%)0/65 (0%)5/65 (7.7%)
Most frequent other events
Most frequent other events
EventParticipants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2
HYPERTENSIONVascular disorders0/843/65
INJECTION SITE EXTRAVASATIONGeneral disorders0/842/65
HEADACHENervous system disorders2/840/65

Baseline characteristics

Safety Population: all participants who enrolled in the study and were dosed with MB-102

Age, Continuous
Age, Continuous(years)Participants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2Total
Mean51.5 ± 12.966.0 ± 8.6257.8 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Participants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2Total
Female373370
Male473279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2Total
Hispanic or Latino342660
Not Hispanic or Latino503989
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants With eGFR ≥ 70 mL/Min/1.73 m^2Participants With eGFR < 70 mL/Min/1.73 m^2Total
American Indian or Alaska Native202
Asian213
Black or African American263157
Native Hawaiian or Other Pacific Islander000
White523082
Other224
Unknown or not reported011
09

Study locations

5 sites
  • Research by Design, LLC
    Chicago, Illinois 60643, United States
  • Centricity Research
    Columbus, Ohio 43213, United States
  • PPD
    Austin, Texas 78744, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78240, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2024, 12 months.

Results were first posted in Mar 2025, 11 months after primary completion.

Of 36 phase 3 interventional studies under Renal Insufficiency, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 77. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Mar 21, 2023
StartActual
Mar 20, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Results first posted
Mar 28, 2025
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05777174
Lead sponsor
MediBeacon
Responsible party
Sponsor
First posted
Mar 21, 2023
Start date
Mar 20, 2023
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Results posted
Mar 28, 2025
Last update
Mar 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relmapirazin

Start the discussion